PMID- 36537187
OWN - NLM
STAT- MEDLINE
DCOM- 20230301
LR  - 20230301
IS  - 2299-8306 (Electronic)
IS  - 0423-104X (Linking)
VI  - 74
IP  - 1
DP  - 2023
TI  - Circulating asprosin, irisin, and abdominal obesity in Chinese patients with type 
      2 diabetes mellitus: a case-control study.
PG  - 55-62
LID - 10.5603/EP.a2022.0093 [doi]
AB  - INTRODUCTION: Studies have suggested that serum asprosin and irisin were involved 
      in type 2 diabetes mellitus (T2DM) and obesity. This study evaluated circulating 
      levels of asprosin and irisin and their associations with anthropometric and 
      metabolic parameters, especially the visceral fat area (VFA) in T2DM patients 
      with abdominal obesity (AO). MATERIAL AND METHODS: In this case-control study, 
      131 patients with T2DM were grouped into an AO group (n = 68) and a non-AO group 
      (NAO) (n = 63) based on their VFA. Anthropometric and metabolic parameters as 
      well as serum asprosin and irisin levels were measured and compared between the 2 
      groups. RESULTS: Compared to the NAO group, the AO group had significantly higher 
      serum asprosin and irisin concentrations (3.67 +/- 1.76 ng/mL vs. 2.85 +/- 0.90 
      ng/mL, p = 0.001; 154.62 +/- 61.87 pg/mL vs. 130.54 +/- 34.89 pg/mL, p = 0.008, 
      respectively) and greater VFA (p < 0.001). Serum asprosin in the AO group was 
      positively associated with weight, waist circumference (WC), hipline, body mass 
      index, fasting blood glucose (FBG), glycated haemoglobin (HbA1c), VFA, 
      subcutaneous fat area, and total abdominal fat area (TAFA), and the serum irisin 
      concentration in the AO group was positively correlated with WC, waist-to-hip 
      ratio (WHR), VFA, and TAFA and negatively correlated with FBG. Stepwise logistic 
      regression analysis suggested that FBG and VFA were independent factors 
      positively associated with serum asprosin, and that FBG was independently, 
      negatively associated with serum irisin, while VFA was independently, positively 
      associated with serum irisin. CONCLUSIONS: Elevated serum asprosin and irisin 
      levels in T2DM patients with AO and their correlations with other metabolic 
      parameters suggest that both are potential therapeutic agents/targets in treating 
      obesity and its related disorders.
FAU - Hu, Guoping
AU  - Hu G
AUID- ORCID: 0000-0001-8843-6383
AD  - Department of Endocrinology, The Third Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui Province, China. huguoping009@126.com.
FAU - Si, Wei
AU  - Si W
AD  - Department of Endocrinology, The Third Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui Province, China.
FAU - Zhang, Qiang
AU  - Zhang Q
AD  - Department of Endocrinology, The Third Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui Province, China.
FAU - Lv, Fang
AU  - Lv F
AD  - Department of Endocrinology, The Third Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui Province, China.
LA  - eng
PT  - Journal Article
DEP - 20221220
PL  - Poland
TA  - Endokrynol Pol
JT  - Endokrynologia Polska
JID - 0370674
RN  - 0 (Fibronectins)
RN  - 0 (FBN1 protein, human)
RN  - 0 (FNDC5 protein, human)
RN  - 0 (Fibrillin-1)
SB  - IM
MH  - Humans
MH  - Case-Control Studies
MH  - *Diabetes Mellitus, Type 2/complications
MH  - East Asian People
MH  - *Fibronectins/blood
MH  - *Obesity, Abdominal/complications
MH  - *Fibrillin-1/blood
OTO - NOTNLM
OT  - abdominal obesity
OT  - asprosin
OT  - irisin
OT  - type 2 diabetes mellitus
OT  - visceral fat area
EDAT- 2022/12/21 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/12/20 03:52
PHST- 2022/07/29 00:00 [received]
PHST- 2022/09/29 00:00 [accepted]
PHST- 2022/09/23 00:00 [revised]
PHST- 2022/12/21 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/12/20 03:52 [entrez]
AID - VM/OJS/J/91170 [pii]
AID - 10.5603/EP.a2022.0093 [doi]
PST - ppublish
SO  - Endokrynol Pol. 2023;74(1):55-62. doi: 10.5603/EP.a2022.0093. Epub 2022 Dec 20.